NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.
Latest news headlines
NICE is updating its guideline on Alcohol interventions in secondary and further education.
08 February 2019
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
NICE and the Canadian Agency for Drugs and Technology in Health (CADTH) have launched a new collaboration to offer parallel scientific advice to the life sciences industry.
06 February 2019
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to access another revolutionary chimeric antigen receptor T-Cell (CAR T-cell) therapy through the Cancer Drugs Fund.
01 February 2019
NICE has announced a collaboration with the body which represents life sciences organisations in the UK.
29 January 2019
Children and young people can be offered digital cognitive behavioural therapy (digital CBT, also known as computer CBT) as a first-line treatment for mild depression.
23 January 2019
Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia.
18 January 2019